Abeona Announces Participation at Upcoming Conferences
September 04 2018 - 8:45AM
Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage
biopharmaceutical company focused on developing novel cell and gene
therapies for life-threatening rare genetic diseases, today
announced that management will participate in two investor
conferences this September. To access the events that are
accessible via live webcasts, please visit the investor section of
Abeona’s website, www.abeonatherapeutics.com.
Citi 13th Annual Biotech Conference Date:
Thursday, September 6th at 10:00 AM ET Panel discussion: “Gene
Therapy: Present & Future” Participant: Carsten Thiel, Ph.D.,
Chief Executive OfficerLocation: Boston, MAWebcast:
https://www.veracast.com/webcasts/citigroup/biotech2018/97204162828.cfm
Jefferies 2018 Gene Therapy Summit Date:
Thursday, September 27th Presenter: Carsten Thiel, Ph.D.,
Chief Executive OfficerLocation: New York, NY
About Abeona: Abeona
Therapeutics Inc. is a clinical-stage biopharmaceutical company
developing cell and gene therapies for life-threatening rare
genetic diseases. Abeona's lead programs include EB-101
(gene-corrected skin grafts) for recessive dystrophic epidermolysis
bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV)
based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and
ABO-101 (AAV- NAGLU), an adeno-associated virus (AAV) based gene
therapy for Sanfilippo syndrome type B (MPS IIIB). Abeona is also
developing ABO-201 (AAV-CLN3) gene therapy for CLN3 disease,
ABO-202 (AAV-CLN1) for treatment of CLN1 disease, EB-201 for
epidermolysis bullosa (EB), ABO-301 (AAV-FANCC) for Fanconi anemia
(FA) disorder and ABO-302 using a novel CRISPR/Cas9-based gene
editing approach to gene therapy for rare blood diseases. In
addition, Abeona is developing a proprietary vector platform, AIM™,
for next generation product candidates. For more information, visit
www.abeonatherapeutics.com.
Investor Contact:Christine SilversteinSVP,
Finance & Investor Relations Abeona Therapeutics Inc.+1 (646)
813-4707csilverstein@abeonatherapeutics.com
Media Contact:Lynn GranitoBerry & Company
Public Relations+1 (212) 253-8881lgranito@berrypr.com
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From Apr 2023 to Apr 2024